Answers are grounded in this paper and cite their sources.
Workshop explores the use of juvenile nonhuman primate models for HIV prevention, suggesting advancements in vaccine efficacy research.
Nonhuman primates (NHPs) have emerged as an indispensable model for studying HIV pathogenesis, vaccines, and therapies. The development of chimeric Simian/Human immunodeficiency viruses (SHIVs) has been constructed by inserting HIV‐1 Env into the SIV (usually SIV mac239 ) backbone, and these have proved essential for evaluating HIV neutralizing antibody dynamics and efficacy in vivo, making studies testing the protective efficacy of human broadly neutralizing monoclonal antibodies (bNAbs) in nonhuman primates possible. The original constructs have been improved in several new SHIV strains to improve binding of the Env to the macaque CD4 receptor by an additional mutation, and further improvements continue to be made. Even with some limitations, NHP models using SHIV infection have contributed substantially to the advancement of HIV bNAb use in both adult and pediatric settings.
No takes yet. Share an insight, caveat, or question.
Hessell et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: